Background. Treatment of multisystem Langerhans cell histiocytosis (LCH) remains difficult. Various regimens of single and multiagent chemotherapy have been used, but a significant proportion of patients fail to respond to treatment. Procedure. We have evaluated the use of cyclosporine A (CSA) in a
Immunosuppressive treatment for chemotherapy-resistant multisystem langerhans cell histiocytosis
✍ Scribed by Minkov, Milen ;Grois, Nicole ;Braier, Jorge ;Rosso, Diego ;Aricò, Maurizio ;Broadbent, Valerie ;Gadner, Helmut ;Ladisch, Stephan
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 64 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Background Reliable prediction of prognosis allowing risk‐adapted therapy remains a major issue in the management of multisystem Langerhans cell histiocytosis (LCH). In a recent publication of the International LCH Study Group, response to initial therapy appears to be a reliable ou
To the Editor: We here describe a 3-year-old-boy who was treated for LCH using vinblastine, etoposide and prednisone according to the International Langerhans Cell Histiocytosis Study I. The patient was admitted in March 1993 with multiple bone lesions, diabetes insipidus and biopsy confirmed LCH. H